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Abstract: The cause of reduced renal mass
(RRM)-saline hypertension is not clear. In our
study, it was aimed to investigate the role of
vasopressin (AVP) in this type of hypertension by using selective V1 antagonist of
AVP. RRM was performed in 32 normotensive male Wistar rats under anesthesia
in which we used a mixture of ketamine (130
mg/kg, i.m.) and chlorpromazine (1.3 mg/kg,
i.m.). After a one-week of recovery period,
all of the rats were given a low sodium diet
and either distilled water (group 1) or 1%
NaCl (group 2) as drinking water for 4
weeks. Five weeks after nephrectomy, indirect blood pressure (BP) and heart rate
(HR) measurements were performed. Group
1 was normotensive but group 2 was hypertensive. One day later, AVP antagonist (10
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Introduction
Reduced renal mass-saline hypertension model is
characterized with high peripheral vascular resistance
and low plasma renin level (1,2). Eventhough some
neural and humoral factors have been hold responsible
to explain these findings, the exact physiological mechanisms have not been identified yet (1,3,4).
Blood pressure increases and decreases cause
changes in the renal sympathetic nerve activity and
heart rate levels. The quantities of these changes are
altered by high Na+ diet via central cardiovascular control mechanism (5). These findings support the possible effect of high Na+ diet on the baroreceptor reflexes.
AVP interacts with the sympathetic nervous system, renin-angiotensin-aldosterone system (RAAS) and
baroreceptor reflex mechanisms (6,7). Any change at
the efficiency of these interacting variables may affect
blood pressure as well as AVP’s pressor response
(4,8,9,10). In previous study, this interaction was discussed for DOCA-salt hypertensive rats and the hyper*

µg/kg) or vehicle was intravenously injected
to normotensive and hypentensive rats under
pentobarbital sodium anesthesia. After injections, BP and HR values were recorded for
30 minutes. The antagonist caused decreases
in the mean arterial pressures of both
groups which were greater in the hypertensive group (p<0.05). In the normotensive
group, HR was increased by the antagonist
(p<0.05). No significant diference was
present between the two groups with regard
to plasma volume and plasma osmolality.
Thus, it was concluded that the pressor effect
of AVP may have been augmented in RRMsaline hypertension.
Key Words: Hypertension, vasopressin, nephrectomy, sodium intake.

tension was explained with the impaired baroreflex responses that augmented AVP’s pressor effect (11).
Similar mechanisms may be involved in the RRM-saline
hypertension model as well. If AVP is the only mediator that is involved in this hypertension, blocking the
V1 receptor on vascular smooth muscle should reduce
the blood pressure. The aim of this study was to investigate the role of AVP in RRM-saline hypertension,
by using selective V1 antagonist.
Material and Methods
Experiments were carried out on 32 male Wistar
rats (DECAM, Adana, Turkey), weighing 311.13±2.12
g (mean±SEM). The rats were housed at constant
room temperature (22˚C) and given normal rat chow
(containing 0.5 % NaCl and 22 % protein) and ordinary tap water. Light was switched on from 8 a.m.
to 8 p.m. Initially, the rats were normotensive. Normotension was determined indirectly by measuring the
systolic blood pressure by using the tail cuff method
(rat tail BP monitor, Harvard Apparatus Ltd., Kent,
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Group I

Indirect blood pressure (A) and
heart rate (B) values at one day
before (open bar) and five weeks
after
(dashed
bar)
the
nephrectomy. C) Direct blood
pressure values at five weeks
after the nephrectomy. I: Group I
(Normotensive), II: Group II
(Hypertensive), indirect: with tail
cuff method. Values are means ±
SEM. *p<0.05 v group I,
**p<0.05 v the values before the
nephrectomy.
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England). The rats having systolic blood pressures of
less than 130 mmHg were accepted as normotensive.
Subtotal nephrectomy was carried out under anesthesia in which we used a mixture of ketamine (130
mg/kg, i.m.) and chlorpromazine (1.3 mg/kg, i.m.).
Through a midline abdominal incision, the right kidney
and approximately 50 percent of the left kidney (both
poles) were removed. The removal of 50 percent of
the left kidney was estimated with the assumption
that both kidneys were equal in weight. Silk ties were
used to excise the poles of the left kidney. A loop of
3-0 silk suture was placed around each pole of the
kidney and then pulled tight. One week after nephrectomy, the rats were divided into two groups; group
1: the rats which were given rat chow containing low
NaCl (0.02 %), and distilled water as drinking water
(n=17), group 2: the rats which were given rat chow
containing low NaCl and 1 % saline as drinking water
(n=15). These different diets were given for 4 weeks.
Systolic blood pressures (SBP) and heart rates
(HR) were measured indirectly at the end of the 5th
week, after nephrectomy. On the next day of the
measurements, tracheostomy (PE-240 tubing, Clay Ad30

ams, Parsipanny, NJ) and femoral artery and vein [PE50 tubing, filled with heparinized saline (10 I.U./ml)]
and bladder (PE-90 tubing) catheterizations were
made under pentobarbital sodium anesthesia (50 mg/
kg, i.p.). The catheter that was inserted into the femoral artery was connected to a Statham P23XL
(Gould, Oxnard, CA) transducer to monitor BP and
HR. Insensible fluid losses were compensated with 0.9
% NaCl via femoral vein with an infusion pump (Cole
Parmer Instrument Company, IL) at a rate of 0.02
ml/min during the experiment. At the end of the stabilization period, which had lasted 30 minutes after
completion of the surgical procedure, a blood of 0.1
ml/100 g body weight was withdrawn for determination of plasma osmolality. Volume replacement
was made by an infusion of cells suspended with 0.9
% NaCl. Osmolality was determined by freezing point
osmometry (Osmette, Precision Systems Inc., MA). Direct SBP, diastolic blood pressure (DBP) and HR recordings (Oscillograph, Model 7, Grass Instrument CO.,
MA) were made at the 15th minute after volume replacement. We used (β-mercapto-β, β Cyclopentamethylenepropionyl1, O-Me-Tyr2, Arg3)-Vasopressin
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The effect of injection of AVP
antagonist (10 µg/kg) or vehicle
on mean arterial pressure and
heart rate. N:Normotensive +
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vehicle. Values are means±SEM.
*p<0.05 v pre-injection value.
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(Sigma, St.Louis, MO) as V1 antagonist of AVP. This
peptide was dissolved in a solution that was composed
of 5 ml of 0.9 % NaCl, 5 mg bovine serum albumin
and 1.5 µl acetic acid and adjusted to pH=6.4 with
NaOH. The concentration of antagonist in this solution was 10 µg/ml. Five weeks after nephrectomy,
group 1 that remained normotensive was divided into
two groups (group N, n=9; group NV, n=8) and
group 2 which developed hypertension was separated
into two groups (group H, n=7; group HV, n=8). AVP
antagonist was injected into group N and group H as
i.v. bolus at a dose of 10 µg/kg. Vehicle injection was
administered into group NV and group HV. SBP, DBP
and HR were recorded for 30 minutes after injections.
Plasma volume was measured by the dilution principle
using the Evans Blue dye technique. For this purpose,
200 µl Evans Blue (Merck, Darmstadt, Germany; 5
mg/ml dissolved in 0.9 % NaCl) was injected intravenously into group NV and group HV, and the tubing
was flushed with 50 µl 0.9 % NaCl at the end of the

BP recording period of 30 minutes. Urine was collected for 10 minutes after the injection of Evans Blue
and a blood sample was withdrawn at the end of the
10th minute. Plasma and urine samples were stored
at -70˚C until analysis. Plasma and urine Evans Blue
concentrations were measured with spectrophotometer
(Schimadzu, UV-1201, Kyoto, Japan) at 605 nm.
Statistics: The results were expressed as the
mean±SEM. Differences between groups were evaluated by Kruskal-Wallis ANOVA. Mann-Whitney U test
was used to reveal significant differences. Wilcoxon
matched pairs test for paired data was used to analyze the BP and HR changes induced by infusions and
to assess other differences within groups. Results with
p<0.05 were considered to be statistically significant.
Results
SBP and HR values that were indirectly measured
31
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Table

Change in Mean Arterial Pressure
(MAP) After the Injection of AVP
Antagonist.

Figure 3.

The amount of decrease in mean
arterial pressure at the 30th
minute after AVP antagonist (10
µg/kg) or vehicle injection. N:
Normotensive+antagonist,
H:
Hypertensive + vehicle. *p<0.05
v group NV or group HV. #
p<0.05 v group N.

Decrease in MAP (Percentage of baseline MAP)
Group/Time (min)
N (n=7)

0
-0.98±
0.92
0.66±
0.92
0.22±
0.22
0.34±
0.34

H (n=7)
NV (n=8)
HV (n=8)

5
-26.28±
3.18*
-33.60±
4.10*
0.64±
0.31
-1.70±
1.35

10

15

-26.73±
4.93*
-35.63±
4.46*
0.85±
0.74
-0.72±
1.22

-23.36±
4.40*
-34.74±
4.02*
0.91±
1.23
-0.38±
1.35

20
-24.48±
3.81*
-34.04±
3.24*
1.98±
0.98
-0.67±
1.51

25

30

-21.89± -16.33±
4.73*
3.61*
-37.13± -33.65±
3.93*
2.60**
4.89±
6.45±
1.71
1.76
-0.85± -0.85±
1.30
1.28

N: Normotensive+antagonist, H: Hypertensive+antagonist, NV: Normotensive+vehicle, HV: Hypertensive+vehicle.
Values are means±SEM. **p<0.05 v N, *p<0.05 v NV or HV.
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at one day before and 5 weeks after nephrectomy are
shown in Figure 1. At the end of the 5th week, indirect SBP and direct SBP and DBP values in group 2
were greater than the values in group 1 (p<0.001,
Figure 1). Direct BP and HR recordings which were
measured 5 minutes before injection of AVP antagonist or vehicle were taken as baseline values. Five
weeks after neprectomy, the increase in indirect HR
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was statistically significant only in group 1 (p<0.01).
No significant differences were determined between
normotensive and hypertensive groups, with regard to
plasma osmolality (group 1: 313.25±7.05 mosm/kg,
group 2: 318.86±8.11) and plasma volume (group
NV: 32.21±1.15 ml/kg, group HV: 32.44±1.59)
V1 antagonist of AVP caused significant decreases
in the MAP of both group N and group H (p<0.05)
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but vehicle did not change the MAP in group NV or in
group HV during the 5-30 minutes after the injection
(Figure 2). The decrease ratios were calculated as percent of baseline mean arterial pressure (MAP). MAP
tended to decrease more in group H than in group N
after the injection (Table). At the 30th minute of injection, difference between the decrease ratios of the
mean arterial pressures in N and H groups was statistically significant (p<0.05, Figure 3). The antagonist
increased HR significantly only in group N (p<0.05,
Figure 2).
Discussion
Since the V1 antagonist of AVP caused decreases in
the mean arterial pressures of both groups, the pressor effect of AVP may be important to maintain BP
level under anesthesia. When any component of the
pressor system like the sympathetic nervous system,
RAAS or vasopressin was blocked, the possible decrease in MAP is compensated by the other two systems (12-16). There are studies about depression of
the sympathetic nervous system (17) and attenuation
of cardiovascular reflexes (7) by pentobarbital sodium.
In our study, the cause of augmented presssor effect
of AVP may be due to a decreased sympathetic efficiency.
It had also been observed in previous studies that
a high sodium diet may lead to hypertension in the
rats which were restricted their renal excretion ability
(1). Pressor effect of AVP might have been increased
in RRM-saline hypertension model, because AVP antagonist tended to cause more decrease in MAP of the
hypertensive group than the normotensive group. In
another study, it has been suggested that AVP is not
a major agent in nephrectomy-salt hypertension (18).
Our finding is contrary to this result. The discrepancy
may be due to different salt-loading periods.
Augmented pressor effect of AVP may be due to
manifestation of its vasoconstrictor effect when it is
considered that AVP leads to a decrease of cardiac
output (7,19). In previous studies, it was reported
that a high salt diet may change the sensitivity of aortic (20) and cardiopulmonary (21) reflexes in Dahl
salt-resistant rats. Hence, investigation of baroreflex
mechanism may contribute to clear the cause of augmented pressor effect of AVP in RRM-saline hypertension when AVP-baroreflex is considered (7).

Though an increase in HR was determined at the
5th week after the nephrectomy in the normotensive
group, in the hypertensive group no significant increase in HR was observed. This difference may be
due to the effect of a low sodium diet on HR when
considered desensitization of arterial baroreceptors because of a low sodium diet (15). The tendency of
heart rates to increase in the normotensive group after AVP antagonist injection is an expected result because of the effect of AVP to produce bradycardia (7).
On the other hand, in the hypertensive group, since
no significant increase in HR was observed after the
injection, the neural mechanisms including baroreflexes
might have been impaired. Actually, there is evidence
that a high sodium diet attenuates the inhibitor response in HR against an increase in BP (5). A possible
change in the sensitivity of baroreflex mechanisms,
which mediate buffering of vasoconstrictor effect of
AVP by decreasing the cardiac output, may contribute
to augmented pressor effect of AVP.
It has been determined that endogenous-digitalislike factor (EDLF) was released (1) and plasma renin
levels were decreased in nephrectomy-salt hypertension. It has been reported that digitalis may augment the release of norepinephrine from the sympathetic nervous system terminals (3). Pressor doses
of angiotensin II attenuate the pressor effect of AVP
(22), whereas norepinephrine can enhance this effect
(7). For these reasons, the pressor effect of AVP may
have also been augmented by EDLF and low renin.
Since no significant difference was observed between the normotensive and hypertensive groups with
regard to plasma volume, this parameter may not be
direct determining factor in RRM-saline hypertension.
This result is in line with the conclusions that include
the independence of blood pressure increase from the
volume expansion in salt-loading hypertension in
anephric rats (23,24). We found no significant difference between the normotensive and the hypertensive
groups regarding to plasma osmolality. This finding is
compatible with the result revealing that the sodium
ion might be a potent stimulator of ADH in addition
to its osmolar action (23)
In summary, AVP may partly be responsible for
RRM-saline hypertension, but it would be appropriate
to investigate the efficiency of the mechanisms that
mediate to buffer the vasoconstrictor effect of AVP, in
order to clarify the cause of augmented pressor effect
of AVP in RRM-saline hypertension.
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